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The emergence of targeted therapies for cancer has created a need for the development
of companion diagnostic tests. Assays developed in recent years are aimed at determining
both the effectiveness and safety of specific drugs for a defined group of patients, thus,
enabling the more efficient design of clinical trials and also supporting physicians when
making treatment-related decisions. Immunohistochemistry (IHC) is a widely accepted
method for protein expression analyses in human tissues. Immunohistochemical assays,
used to localize and quantitate relative protein expression levels within a morphological
context, are frequently used as companion diagnostics during clinical trials and also fol-
lowing drug approval. Herein, we describe established immunochemistry-based methods
and their application in routine diagnostics. We also explore the possibility of using IHC to
detect specific protein mutations in addition to DNA-based tests. Finally, we review alter-
native protein binders and proximity ligation assays and discuss their potential to facilitate
the development of novel, targeted therapies against cancer.
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INTRODUCTION
Throughout recent decades, our understanding of the molecular
basis of cancer development has dramatically improved. This is
reflected in the growing number of targeted cancer therapies and
significantly affects today’s standard of care in oncology. Never-
theless, a prerequisite for an effective, targeted cancer treatment
concerns the selection of patient, which creates a growing demand
for reliable companion diagnostic devices. The rationale behind
such developments is to ensure that treatment is not withheld
from patients whom it may benefit while at the same time protect-
ing them from overtreatment, the risk of unnecessary side effects
and, most importantly, a delay in receiving treatment with a more
suitable agent.
Companion diagnostics also play an important role during the
pre-clinical stages of drug testing. A potent effect observed in a
small patient population may be missed by the absence of a reliable
companion diagnostic test. Conversely, a novel subset of patients
may be found to benefit from treatment or no difference in effi-
ciency may be detected, regardless of biomarker positivity. These
issues pose a challenge to the parallel development of drug and
companion diagnostic tests and consequently, the latter should be
fully validated before the initiation of clinical trials and the trial
design adjusted accordingly (1). Despite much advances, the cor-
responding regulatory framework is still incomplete and while the
US Food and Drug Administration (FDA) dictates a stringent pre-
market approval procedure for all companion diagnostic devices,
similar legislation is still under review in Europe (1). Currently,
only 19 companion diagnostic devices have been approved by the
FDA, 10 of which are intended for the detection of the human




Most companion diagnostic tests used in a clinical setting are
based on immunohistochemistry (IHC), real-time reverse tran-
scription PCR (qRT-PCR), or in situ hybridization (ISH). With
regard to ISH, assay systems based on either fluorescent (FISH)
or colorimetric (CISH) signal detection have been established and
each testing modality is associated with a number of advantages
and disadvantages (Table 1).
While the scope of companion diagnostics is broad, with this
review we will focus on techniques designed to detect proteins in
formalin-fixed, paraffin-embedded (FFPE) tissue. We will discuss
currently applied companion diagnostic tests which use IHC and
also novel developments regarding mutation-specific antibodies,
in situ proximity ligation assays (PLA), and alternative protein
binders.
APPLICATION OF IMMUNOHISTOCHEMISTRY IN CLINICALLY
USED COMPANION DIAGNOSTICS
ESTROGEN RECEPTOR
The introduction of tamoxifen, a selective estrogen receptor (ER)
modulator, over 30 years ago has revolutionized the clinical man-
agement of breast cancer. However, since significant treatment
benefits were only observed in ER-positive patients (2, 3), com-
panion diagnostic testing became imperative. Originally, various
ligand binding assays (LBAs) were used to quantify the expres-
sion of ER, however, they required homogenization of fresh frozen
tumor material and were thus laborious in their execution. With
the development of monoclonal antibodies targeting the ER and
antigen retrieval methods for the use of FFPE tissue, LBAs were
soon replaced and IHC became the standard diagnostic tool. Sev-
eral grading systems were subsequently introduced to describe
IHC-based ER expression levels, including (1) Allred score (range:
0–8) (4), (2) Quick score (range: 0–7) (5) (both of which are based
on the sum of fraction and intensity units of the stained cells), (3)
J -score (range: 0–3, based on the fraction of stained cells) (6)
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Table 1 | Advantages and disadvantages of currently used companion diagnostic techniques.
Technique Advantage Disadvantage
IHC Routinely performed; low technological requirements;
time and cost effective; preservation of histological
information; suitable for small tumor samples
Semi-quantitative; subjective interpretation of results; variability dependent on
fixation procedure, staining protocol, and antibody selection
qRT-PCR Quantitative; large dynamic range No histological information retained; contamination of test results by
stromal/normal tissue possible; increased technological requirements; increased
time and cost requirements; variability dependent on tissue quality, RNA
extraction/processing procedures and primer/probe selection
ISH Quantitative for genetic alterations; higher
reproducibility
Increased technological requirements (especially for FISH); increased time and
cost requirements; added expertise in result interpretation necessary
IHC, immunohistochemistry; qRT-PCR, quantitative real-time PCR; ISH, in situ hybridization; FISH, fluorescent in situ hybridization; CISH, colorimetric in situ
hybridization.
and (4) H-score (range: 0–300, based on the product of fraction
and the intensity unit of stained cells) (7). Differences between
positive/negative definitions together with variations regarding
antibody clones, tissue fixation, antigen retrieval, and detection
protocols, all contributed to a significant rate of variability in
ER detection (8–10). For instance, a study headed by the UK
National External Quality Assessment Scheme for Immunocyto-
chemistry (NEQAS-ICC) reported false negativity rates ranging
from 30 to 60% following the testing of a standardized sam-
ple with low ER expression by 200 laboratories throughout 26
countries (8).
Due to the historic nature of ER testing, there are currently no
FDA-approved companion diagnostic devices available. To mini-
mize inter-laboratory variation, the American Society of Clinical
Oncology and the College of American Pathologists (ASCO/CAP)
have recently published a document outlining their recommenda-
tions for the immunohistochemical testing of ER in breast cancer
(11). The optimal testing conditions and tissue handling require-
ments were defined together with guidelines for both the internal
and external quality assurance procedure. The same guidelines
were also applicable to the detection of the progesterone recep-
tor (PR) via IHC. PR is located downstream of ER and a positive
PR test result may be indicative of an intact estrogen signaling
cascade (12). This line of thinking was corroborated by the find-
ing that patients with PR positive tumors had a better prognosis
than patients with ER-positive/PR negative breast cancers (13).
Alternative methods for the detection of ER and PR are contin-
uously under investigation and Oncotype DX is one such exam-
ple. This is a qRT-PCR-based assay system designed to estimate
the probability of distant tumor recurrence in tamoxifen-treated,
node-negative breast cancers (14) and measures the expression
PR and ER, together with 19 other genes, in mRNA extracted
from FFPE tissue. Proof-of-concept studies on the applicability
of Oncotype DX as a companion diagnostic tool for tamoxifen
treatment reported varying conclusions. In a study supported by
Genomic Health Inc., Badve and colleagues reasoned that ER/PR
determination using Oncotype DX performed comparably well to
IHC-based detection systems (15). This was in contrast to an inde-
pendent evaluation by Kraus et al. who concluded that IHC was
superior to the Oncotype DX qRT-PCR-based test, not only due
to higher sensitivity but also the lower cost, the ease of application
and the preservation of morphological information (16).
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
Overexpression of the HER2 protein and/or amplification of
the HER2-encoding gene have been associated with an unfa-
vorable prognosis in several types of cancer, including breast,
gastric, and pancreatic cancer (17–19). Trastuzumab (Herceptin),
an antibody-based inhibitor, was the first HER2-targeted drug
to be approved for the treatment of breast cancer and has since
been shown to significantly improve survival in a metastatic and
adjuvant setting (20, 21). Numerous studies support the close
relationship between HER2 positivity and trastuzumab respon-
siveness (20, 22) and bearing in mind that a HER2-amplification
rate of approximately 25% occurs in breast cancer, initial clinical
trials may not have yielded significant data had no pre-selection
of patients according to HER2 status taken place (23). Since gene-
amplification is the primary cause of HER2 overexpression (24),
both FISH- (or CISH-) and IHC-based companion diagnostic
devices have been approved by the FDA. Nevertheless, the ini-
tial evaluation of HER2 status is usually performed using an
IHC-based method and only ambiguous (or equivocal) cases are
subjected to FISH reflex testing.
Substantial inter-laboratory variations in test results are an
inherent problem when considering IHC-based tests. Similar to
the guidelines established for ER, ASCO/CAP has produced rec-
ommendations for HER2 testing in breast cancer (25, 26). In
contrast to the instructions for the commonly used FDA-approved
HercepTest (Dako), which states that a finding of more than
10% of cells with strong, uniform membrane staining qualifies
as a positive result, the ASCO/CAP guidelines require complete
intense membrane staining in >30% of cells in order to qualify
as a positive test result following IHC testing. In addition, unlike
the FDA-approved cut-off ratio of 2.0 for HER2/Chromosome
17 centromere (CEP17) testing via FISH (or four HER2 copies in
assays without internal CEP17 probes),ASCO/CAP considered the
range of ratios between 1.8 and 2.2 (or four to six HER2 copies) as
equivocal and stated that only cases with HER2/CEP17 ratios>2.2
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(or more than six copies of HER2) could be deemed to be positive
based on FISH analysis. The aim of the new ASCO/CAP guide-
lines was to reduce the number of inconclusive cases and although
some groups were positive to these new definitions (27, 28), oth-
ers saw no added benefit (29). While high concordance between
IHC- and FISH-based HER2 testing was demonstrated by several
studies, thus justifying the use of routine IHC as an initial test
(30), critics are keen to highlight the technical superiority of FISH
over IHC and consequently advocate FISH as the gold standard
for HER2 testing (31). Hence, it is evident that more conclusive
studies on the clinical significance of both testing modality are
required.
EPIDERMAL GROWTH FACTOR RECEPTOR
The epidermal growth factor receptor (EGFR) is a prominent
therapeutic target in both colorectal and non-small cell lung can-
cer (NSCLC). In colorectal cancer, it is primarily targeted by the
monoclonal antibody-based drugs cetuximab and panitumumab.
These drugs target the extracellular domain of the EGFR and block
down-stream signaling. Clinical trials for both agents initially
required the pre-selection of patients based on positive expres-
sion of the EGFR protein, as determined by IHC, however, it soon
became evident that IHC-based protein expression levels did not
correlate with therapy outcome (32,33) and that even patients with
EGFR-negative tumors may benefit from EGFR-targeted therapy
(34, 35). The causes for this discrepancy may be of a technical
nature and connected to the variability/sensitivity of immuno-
histochemical techniques, or they may be a direct consequence
of biological determinants. For instance, metastatic tumors may
have lost the expression of EGFR, rendering them unresponsive
to therapy (36). In addition, Chung and co-workers reasoned that
antibodies used within IHC-based detection systems were unable
to discriminate between high- and low-affinity EGFRs. Conse-
quently, the relative distribution of such high- and low-affinity
EGFRs within colorectal cancer tissue may be crucial in deter-
mining the response to therapy (34). Furthermore, it has been
noted that therapeutic antibodies that target EGFR may induce
antibody-dependent, cell-mediated cytotoxicity, resulting in an
indirect beneficial effect owing to the recruitment of cytotoxic
immune cells such as monocytes and natural killer cells to the
tumor (34).
While the immunohistochemical detection of EGFR expression
did not prove to be decisive in determining the clinical response,
promising data has been generated in support of using the EGFR
gene copy number as a predictive biomarker for EGFR-targeted
therapy (37). Nevertheless, in order to achieve definitive proof and
to facilitate the development of standardized testing modalities
further investigation is required. In NSCLC, EGFR is targeted pri-
marily using the small molecule inhibitors gefitinib and erlotinib.
In contrast to colorectal cancer, mutations within the EGFR in
NSCLC are common and mutational testing is recommended for
all NSCLC cases (38). The application of mutation-specific anti-
bodies for this purpose is discussed below. A further distinguishing
feature regarding the testing of EGFR in colorectal cancer and
NSCLC is that in the latter, IHC positivity or high EGFR gene
copy numbers showed no conclusive correlation with treatment
response (38).
V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE
HOMOLOG
Immunohistochemistry provides an excellent tool for the differ-
ential diagnosis of gastrointestinal stromal tumors (GIST). This
is largely due to the fact that greater than 85% of GIST test
positive for v-kit Hardy-Zuckerman 4 feline sarcoma viral onco-
gene homolog (KIT), in contrast to the negative result generated
by most other mesenchymal tumors (39, 40). Imatinib mesylate
(Gleevec, Novartis, Basel, Switzerland) is a specific tyrosine kinase
inhibitor that exhibits high therapeutic activity in patients with
chronic myeloid leukemia by targeting the fusion protein BCR-
ABL (41). Additional targets of imatinib mesylate include the
platelet-derived growth factor receptor (PDGFR) and KIT. For
patients with unresectable or metastatic GIST, a positive immuno-
histochemical staining for KIT was initially required as an entry
criteria into clinical trials investigating the efficacy of imatinib
mesylate (42, 43). Significant clinical responses were recorded
and this revolutionized the management of advanced GIST, a
malignancy that had previously failed to respond to conventional
chemotherapy. Activating mutations within the KIT gene and, to
a lesser degree, PDGFR, are commonly found in patients with
GIST and depending on their location within the coding region
of the respective gene, they are highly correlated with the likeli-
hood of a response to imatinib mesylate treatment (44, 45). That
notwithstanding, since a small percentage of patients with GIST do
not express detectable levels of KIT or do not harbor mutations
within KIT/PDGFR (44–46) IHC or mutational analysis should
not be used to deny treatment with imatinib mesylate since these
patients may still be sensitive to this therapy.
ANAPLASTIC LYMPHOMA KINASE REARRANGEMENTS
In addition to EGFR, the anaplastic lymphoma kinase (ALK)
represents a second therapeutic target in NSCLC. Chromoso-
mal rearrangements involving the associated gene have been
detected in approximately 5% of cases, most frequently resulting
in the fusion to echinoderm microtubule-associated protein-like
4 (EML4) and the constitutive expression of a chimeric tyrosine
kinase protein (47, 48). Second-line treatment of NSCLC patients
with confirmed ALK rearrangements, using the small molecule
inhibitor crizotinib, has recently been shown to significantly pro-
long progression-free survival compared to standard chemother-
apy (49). The current “gold standard” for ALK rearrangement
testing is dual-color break-apart FISH. However, interpretation
of test results may be challenging since EML4 and ALK are located
on the same chromosome, resulting in limited separation of the
5′ and 3′ probes. To define a positive test result, only signals sep-
arated by more than two signal diameters and/or single 3′ signals
(correlating to the ALK kinase domain) should be counted. In
addition, at least 50 cells should be reviewed with a positive sig-
nal detectable in at least 15% (50). The immunohistochemical
detection of ALK has been considered as an attractive addition
to routine FISH testing. Since ALK is not expressed in lung tis-
sue unless driven by promoter rearrangement, a good correlation
between IHC and FISH results and low IHC background staining
have been reported. In addition, a number of studies confirm that
IHC-negative cases are almost exclusively negative in FISH analy-
sis and therefore indicate that IHC could be applicable as a quick
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and cost-effective screening tool for ALK rearrangements (51–54).
FISH reflex testing for all IHC positive cases has been proposed,
somewhat similar to the evaluation strategy for HER2 (55). Inter-
estingly, the percentage of ALK rearrangement positive cells during
FISH evaluation did not significantly correlate with the response
to crizotinib (56). Nonetheless, comprehensive data on the cor-
relation between the intensity of ALK staining as determined by
IHC and treatment response is still lacking.
MUTATION-SPECIFIC ANTIBODIES
The selection of patients for a targeted cancer treatment fre-
quently relies on the detection of specific gene mutations. The
routinely applied techniques are generally based on the isolation
of chromosomal DNA from fresh, frozen or FFPE material and
analysis can involve various techniques such as mutation-specific
real-time PCR, direct sequencing, mass spectrometry, mismatch
ligation assays, high-resolution melting curve assays, or denatu-
rating high-performance liquid chromatography, among others.
A common drawback relates to the fact that information on tis-
sue morphology is lost and also that “contamination” of tumor
material with normal cells may hamper detection or obscure the
results. In addition, increased demands on sample size and qual-
ity and extra requirements regarding technology and expertise,
associated with higher cost and expenditure of time, frequently
apply. The development of mutation-specific antibodies and their
application in routine IHC may provide a convenient addition to
DNA-based profiling techniques.
BRAF V600E
The v-raf murine sarcoma viral oncogene homolog B1 (BRAF)
represents an outstanding target for the development of a
mutation-specific antibody. Mutations of the associated gene
occur in a range of human malignancies including cutaneous
melanoma, colorectal cancer, NSCLC, papillary thyroid cancer,
and hairy-cell leukemia (57–59). By far, the most common BRAF
mutation results in the substitution of valine for glutamic acid
at position 600 (V600E), leading to the constitutive activation
of the protein’s kinase domain. In human cutaneous melanoma,
mutated BRAF has been detected in 40–50% of cases, with up
90% of these alterations concerning the V-E substitution at codon
600 (60). Vemurafenib and dabrafenib are two potent small mole-
cule inhibitor drugs that specifically target BRAF V600E and have
demonstrated remarkable response rates in metastatic melanoma
patients (61, 62). Mutational testing of the patient tumor mate-
rial is required before commencement of treatment and is to
date commonly based on the detection of genomic alterations.
As an addition to DNA testing, Capper et al. recently proposed
a mutation-specific antibody for the detection of BRAF V600E
in FFPE tissue specimens by means of IHC (Figure 1) (63). The
results obtained from using this antibody to determine the BRAF
mutational status in melanoma and thyroid cancer samples were
identical to those achieved following DNA sequencing-based pro-
filing. These results have since been substantiated by numerous
studies with similarly high levels of specificity and sensitivity (up
to 100%, respectively) (64–68).
In samples where the number of tumor cells is low, IHC-based
BRAF testing was suggested to be more sensitive than direct DNA
sequencing or high-resolution melting curve analysis (64, 65). In
addition, IHC-based staining results showed low inter-observer
variability (68). Nevertheless, despite the benefits of using IHC-
based methods for determining the presence/absence of mutations
within the BRAF gene, the presence of (non-specific) strong,
FIGURE 1 | BRAFV600E mutation-specific antibody staining.
Immunohistochemical staining examples of the BRAFV600E
mutation-specific antibody VE1 are presented for a BRAFV600E-positive and a
BRAFV600E-negative case of melanoma, colon cancer, and thyroid cancer,
respectively. BRAFV600E-positive staining is generally detected as a granular,
cytoplasmic signal that can easily be distinguished from BRAFV600E-negative
cases. In the presented example images, 3,3′-Diaminobenzidine (DAB) was
used as a chromogen.
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nuclear staining may complicate the assessment of staining results.
In addition, false-negative IHC results may occur due to unsuit-
able or incomplete tissue fixation, the presence of necrotic or
pre-necrotic tissue areas or low levels of total protein expres-
sion (63, 64). The latter may be controlled for through the use
of an additional antibody capable of detecting total BRAF pro-
tein expression. With regard to the intra-tumor heterogeneity of
BRAF V600E, only few cases with non-homogenous expression
have been observed following immunohistochemical detection
(67, 69). These results are in direct contrast to previous reports
describing significant variability of BRAF mutational status among
individual cells within a tumor and warrant further investiga-
tion (70, 71). Regarding the possible relationship between BRAF
V600E protein expression and clinical outcome, no significant
correlation was seen between the percentage of BRAF V600E
positive tumor cells and the response to treatment with either
dabrafenib or vemurafenib (72). Similarly, the total intensity of
mutation-specific antibody staining did not significantly correlate
with patient outcome.
EGFR L858R AND E746_A750del
Epidermal growth factor receptor mutations have been detected
in 2–17% of NSCLC patients from Europe and the United States,
however, the mutational frequency increases to 30% when analyz-
ing cases from East Asia (73–75). Specific mutations, in particular
those affecting the EGFR kinase domain, have been associated
with response to gefitinib and erlotinib treatment (76, 77). The
two most common types of EGFR mutations are in-frame dele-
tions of exon 19 and a leucine to arginine substitution at codon
858 (L858R) in exon 21. Taken together, alterations at these
sites account for up to 90% of all EGFR mutations (78). Exon
19 deletions may affect a varying number of nucleotides. For
example, E746_A750del results in a five amino acid deletion in
the corresponding protein and is the most common deletion
detected, occurring in approximately 70% of cases (79). The appli-
cation of mutation-specific antibodies designed to target L858R
and the E746_A750del modification, have yielded varying lev-
els of detection specificity and sensitivity. For L858R, several
studies reported sensitivity values in the range of 70–100% and
specificities exceeding 95% (79–83). While these results were
promising, sensitivities as low as 36 and 40% have also been
described for the same antibody clone (84, 85). Similarly, regard-
ing the E746_A750del-specific antibody, the same studies pub-
lished sensitivity and specificity values of 40–100% and 95–100%,
respectively. The possible sources of variation are numerous and
include the application of different scoring systems, discrepancy
between the definitions of positivity/negativity, different DNA-
based reference techniques, different tissue fixation methods, and
the types of specimens analyzed. While initial attempts to deter-
mine optimal tissue preparation and staining evaluation have
been presented (86), additional steps toward a standardized pro-
tocol for the detection of EGFR mutations using IHC should be
undertaken.
The overall high levels of specificity associated with IHC-based
EGFR-mutational testing imply that IHC may be suitable as a pre-
screening tool for the identification of NSCLC patients that are eli-
gible for EGFR-inhibitor treatment. Since a number of mutations
are not currently detectable by antibody-based profiling, the addi-
tional testing of IHC-negative cases using direct DNA sequencing
or similar assays is necessary (79, 81). The applicability of IHC
in predicting response to EGFR-targeted therapy remains contro-
versial. Confirming the importance of EGFR-mutational status for
treatment response, positive IHC staining has been associated with
longer progression-free survival compared to IHC-negative or -
equivocal cases (83, 87). In addition, high mutant EGFR expression
(as defined by the sum of scores for fraction and intensity) was
significantly related to elevated progression-free survival but not
overall survival (88) and a fraction of positive tumor cells exceed-
ing 50% of all cells predicted better response to EGFR inhibition
treatment in univariate but not multivariate analysis (89). Despite
the aforementioned results, a study by Kato and co-workers could
not detect a significant correlation between IHC staining and treat-
ment response or survival (82). Shortcomings in the significance
of IHC-based detection methods in predicting survival benefit, in
particular when compared to DNA-based techniques, may occur
due to the limited mutation spectrum detected via IHC. Fur-
thermore, EGFR-mutation-specific antibodies have been shown
to occasionally detect mutations associated with EGFR-inhibitor
resistance via mechanisms that are not yet fully understood (84).
ALTERNATIVE PROTEIN BINDERS
In situ affinity-based detection of proteins remains one of the best
sources of information about either the healthy status of an indi-
vidual tissue or potential pathological changes, and is thus applic-
able within several medical settings. Molecular imaging allows for
the early detection and classification of many human diseases
and, when specific, permits improved, target-directed therapies.
Molecules generated through immunization such as polyclonal,
monospecific polyclonal, and monoclonal antibodies continue to
be the best established and most widely used binders in diag-
nostics (90, 91). Methods for the detection of proteins based
on antibody recognition often encounter problems due to poor
selectivity and/or sensitivity (92). Poorly characterized antibodies
and/or insufficient quality control often render them as unsuit-
able for demanding applications such as companion diagnostics
(93). Commercially available antibodies frequently perform very
differently within various laboratories and often do not perform
as advertised, thus raising doubts regarding their reliability when
incorporated into assays requiring high specificity (94). Antibodies
can be biochemically and physiologically modified and use of their
derivatives, such as single chain variable fragments (scFv) or Fab
fragments, may result in the improved detection of a wide range of
target molecules (Figure 2) (95). Currently only a few antibodies
and recombinant proteins are used within clinical settings, largely
due to the reasons outlined above. Recombinant binders that are
generated in immune-free, in vitro-based approaches, hold the
potential of taking priority over conventional antibodies (96). Sta-
bility, specificity, ease of manipulation, low cost, high throughput,
and reproducibility of production are some of the advantages that
make novel scaffold molecules highly desirable (97). Alternative
binders are promising molecules for novel approaches in indi-
vidualized medicine (Figure 2). They can serve as personalized
molecular imaging tools for in vivo, live diagnostics of the changes
occurring in the expression of markers following treatment (95).
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FIGURE 2 | Schematic representation of binder formats.
RECOMBINANT ANTIBODY FRAGMENTS
Antibody fragments are generated in order to obtain binders
with improved characteristics, compared to conventional anti-
bodies, but similar functional and recognition properties. Fab
and F(ab)2 fragments are antigen-binding fragments generated
after proteolysis of full length antibodies. Single chain vari-
able fragments (scFvs) are smaller than Fab fragments and are
composed of genetically linked light and heavy chains contain-
ing variable regions. These molecules can also exist as dimers
(98). Another class of antibody-derived antigen-binding mole-
cules, termed nanobodies, are small, single-domain polypeptides
derived from the variable part of the heavy chain (VHH) of
light-chain deficient antibodies that were originally discovered in
camelids (camels, llamas) (99, 100). Their reduced size, greater
stability and solubility, and antibody-like binding characteristics
make nanobodies ideal for use in the targeting and imaging of
antigens in live cells, protein precipitation in vivo, and targeted
enzymes modulations (101–103). As a result of their smaller size
(only 15 kDa), nanobodies can bind to epitopes that are hidden
or shielded and reach affinities within the range of nanomolar
to picomolar. Nanobodies are highly specific for their targets and
have no known cross-reactivity to structurally related proteins,
which makes them excellent tools for targeting kinases and tyro-
sine phosphatases. In addition, nanobodies have technological
advantages that render them superior to conventional antibod-
ies. They are easily modified to avoid chemically reactive groups
such a primary amines or to alter the primary amine number to
allow more selective and controlled chemical conjugation. The
selection of binders for certain applications is usually based on
their performance in experimental settings and depends on their
preference for particular epitopes and the accessibility of binding
sites.
AFFIBODY MOLECULES
Affibody molecules are small (∼7 kDa), alpha-helical Z -domain
of Staphylococcal protein A, immune-independent affinity mol-
ecules that target a wide range of proteins (104, 105). They can
be produced in functional form both via recombinant expression
in Escherichia coli or peptide synthesis. They possess picomo-
lar affinities, are highly soluble and stable. In addition, they are
cysteine-free which prevents non-specific binding events when
applied to tissues. Furthermore, the lack of cysteine provides
an opportunity for site-specific labeling through the introduc-
tion of unique cysteine molecules. High affinity affibodies were
engineered against targets such as the IL2 receptor, Alzheimer’s
amyloid-beta peptide or EGFR (106–108). They have been used
in various types of experiments and are intended for both
in vivo and in vitro imaging and also therapeutic applications
including the detection of HER2 within different experimental
settings (109, 110).
DESIGNED ANKYRIN REPEAT PROTEINS
Designed ankyrin repeat proteins (DARPins) are potent alter-
natives to conventional antibodies. They detect antigens with
high specificity and picomolar affinity, are independent of target
immunogenicity and possess attractive molecular properties such
as small size and high stability (111). They are synthetic, non-
immunoglobulin binding proteins that form scaffolds containing
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tandem repeats of an elementary, structural motif, typically com-
posed of 33 amino acid residues folded into a β-turn followed
by two antiparallel α-helices. A single protein may contain up to
29 repeats of this motif. The production of DARPins does not
require the use of animals at any step, therefore permitting the
large scale, parallel production of variable binders. DARPins are
correctly folded in both prokaryotes and eukaryotes, due to the
absence of disulfide bonds, which enables their use in a variety of
functional assays (112). They can easily be genetically modified
to form fusion proteins and site-specifically targeted for chemi-
cal conjugation. DARPins against a wide range of protein targets,
including extracellular, intracellular, and membrane proteins, were
generated with high yield from synthetic libraries and success-
fully used as replacements for conventional antibodies. One such
example is the DARPins generated against HER2; these displayed
higher specificity and similar sensitivity when compared to FDA-
approved antibodies for the in situ identification of HER2 expres-
sion status in FFPE breast cancer tissue (113). DARPins can easily
be made functional for use in various biomedical applications
through the introduction of site-specific, clickable modifications.
Such alterations do not affect their physical properties (114).
APTAMERS
Aptamers are a class of small, synthetic, self-folding, and single-
stranded RNA or DNA molecules that form secondary and tertiary
structures and specifically bind to proteins, small molecules, or
other cellular targets such as nucleic acids (115, 116). They are
comparable to antibodies in terms of their target recognition capa-
bilities, their binding affinities, and the diversity of applications
that they can be used in; however, they possess numerous signifi-
cant characteristics that render them advantageous over their pro-
tein equivalents. Aptamers are highly specific, non-immunogenic,
redox-insensitive, and temperature- and pH-tolerant. In addition,
they do not have hydrophobic cores which are usual in proteins
and, therefore, they do not aggregate. In order to select aptamers,
information on protein conformation is not required, a feature
which can be useful for screening for unidentified disease biomark-
ers. Aptamers can be generated through cell-based aptamer selec-
tion that utilizes differences between the molecular signatures of
any two different cell types. The selected aptamers selectively bind
to an unknown protein within one cell type only, are cross-linked
to their targets and once the complex is purified the targets can
be analyzed by mass spectrometry (117). Therefore, the cell-based
selection of aptamer molecules has great potential for the devel-
opment of specific probes suitable for biomarker discovery and
companion diagnostics development. Since chemical synthesis is
a process that is well defined and highly reproducible, the produc-
tion of aptamers can easily be scaled up. They can be synthesized
with specific, custom tailored functional groups attached to 5′
or 3′ termini which creates an easy approach to conjugation and
multiplexing in situ assays. Furthermore, aptamer conjugations do
not generally alter their binding affinity. With advances in imag-
ing techniques, aptamers are already considered as prospective
reagents for in situ targeting. To date, several aptamers have been
developed against important clinical targets such as PDGF, von
Willebrand factor (vWF), E-selectin, vascular endothelial growth
factor (VEGF), and prostate specific membrane antigen (PSMA)
and their applicability within a clinical setting is currently being
investigated (118–121).
IN SITU PROXIMITY LIGATION ASSAY
Using traditional IHC techniques, the level of protein expression
can easily be determined. However, the functional status of a cell
cannot be evaluated by the level of expressed protein alone. The
activity of signaling pathways, as assessed by the analysis of post-
translation modifications (PTMs) and protein interactions, needs
to be determined and taken into consideration (122). Cancer does
not consist of a homologous mass of cells but of complex, hetero-
geneous cell populations that are affected by interactions with each
other and the surrounding environment. Therefore, the analysis
of cancer tissue at single cell resolution provides a much better
understanding of the differences in signaling status and activity
(123). In situ PLA enables a localized and specific detection by
utilizing oligonucleotide-conjugated antibodies to determine the
proximity between one or more targeted epitopes. This makes it a
suitable method for detecting molecular events in cells and tissue,
for example the status of a signaling pathway. The use of two inde-
pendent binders and the additional requirement of proximity for
reporting enable the specific detection of proteins, protein–protein
interactions, and PTMs (124). Proximity ligation converts the
recognition of a protein, protein complex, or PTM by two or more
antibodies into an amplifiable, circular DNA molecule (Figure 3).
Upon proximal binding of a pair of oligonucleotide-conjugated
antibodies (PLA probes), the oligonucleotides guide the formation
of a circle after applying two additional, single-stranded DNA mol-
ecules. This circular DNA molecule is then ligated and amplified
by phi29 polymerase within a rolling-circle amplification (RCA)
reaction, resulting in a localized, concatameric product. The latter
is visualized by hybridization of detection oligonucleotides labeled
with fluorophores or horse radish peroxidase (Figure 3) (125).
Due to the environment of fixed cells and tissue the amplification
product will collapse into a bundle with a diameter of approxi-
mately 1µM (126) that can then be visualized as a bright dot that
is quantifiable and easily distinguished from the background (127).
Heterogeneity within a sample increases the demands on the
dynamic range of a method in order to allow for the detection of
both abundant and scarce targets within the same sample. In situ
PLA uses an amplifiable DNA circle as a reporter molecule and
by using reagents that give rise to three variants of the reporter
DNA circles and adding them at decreasing concentrations the
dynamic range of the PLA is increased. By labeling the circles
with different fluorophores, the readout can be adjusted to the
fluorophore whose concentration gives rise to quantifiable and
easily distinguishable signals. In a heterogeneous sample, different
readout fluorophores can be used for different parts of the sam-
ple, enabling the detection of a target that varies greatly within
the sample without the risk of signal saturation. As the size of a
patient sample is often limited, this approach reduces the need
to optimize the binder concentration and enables the evaluation
of patient samples where knowledge on the expected results is
limited (128).
Multiplex in situ PLA permits the parallel analyses of mul-
tiple protein complexes involved in signaling pathways directly
in tissue and cells thus making it possible to compare levels of
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FIGURE 3 | Proximity ligation assay. (A) Two probes stay in close
proximity by binding to a protein or two proteins present in one
complex. (B) They are joined and circularized by DNA ligation upon
introduction of linear connector oligonucleotides. After ligation,
rolling-circle amplification (RCA) is initiated. One of the proximity
probes is used as a primer. (C) The single-stranded RCA products are
hybridized with labeled detection oligonucleotide complementary to a
multiplied motif in the sequence of the RCA product. The detection
oligonucleotide can be labeled with fluorophore (D) or a horse radish
peroxidase (E).
protein complexes between individual cells and also providing
information regarding the spatial distributions of these com-
plexes. A tag-specific sequence within the PLA probe targeting
a protein gives rise to a DNA circular molecule that carries infor-
mation on the identity of the target protein. The amplified tags in
the RCA products can then be visualized using oligonucleotides
labeled with different fluorophores, to uniquely recognize the tag
sequences corresponding to a certain target (129). In situ PLA has
been shown to provide valuable information about the status of
signaling pathways by detecting molecular events such as dimer-
izations, the formation of protein complexes and PTMs. It enables
the detection of activity at different levels within a signaling path-
way, thereby enabling specific aberrations to be pinpointed. In situ
PLA has been utilized in studies investigating both EGFR dimer-
ization and receptor activation, which has been proposed to play
a crucial role during tumor progression, and also the develop-
ment of drug resistance. Dimerization and aberrant activity has
been shown to be independent of EGFR expression, explaining
why the deregulated expression of the EGFR in several types of
human malignancies was shown to have limited value as a prog-
nostic or diagnostic marker. Receptor dimerization events detected
by mutation-specific PLA appeared to be more suitable for the
selection of patients for EGFR-targeted treatment (130).
Similarly, the overexpression of human epidermal growth fac-
tor receptors (HERs) has been linked to poor prognosis in patients
with early breast cancer. Dimers containing the HER2 isoform
were shown to be more stable and have prolonged active signaling
compared to HER2 deficient dimers. Elevated levels of HER2-
HER2 and HER2-HER3 complexes detected by PLA showed a
significant association with decreased recurrent-free survival and
a reduction in overall survival of breast cancer patients, prov-
ing that PLA and the detection of cellular signaling processes can
be successfully implemented in studies on prognostic markers in
clinical specimens (131). Through the application of in situ PLA,
it is now possible to screen for the effects of a drug treatment on
intracellular signaling, providing information on the specific level
of signaling pathways. Being able to study primary cell lines and
patient tissue sample gives valuable information of the signaling
status within a specific tumor and allows to predict the response
to a certain therapy (132). PLA technologies have been used to
address a variety of biomedical problems and demonstrated the
potential to address some difficulties, both concerning the valida-
tion of biomarkers and the applicability for clinical diagnostics.
Implementing PLA techniques as an alternative to IHC in every-
day laboratory practice allows for a more precise and quantitative
evaluation of antibody performance characteristics and their suit-
ability for an anticipated analytical use. Application of the PLA
technique provides an opportunity to develop a high-quality pro-
cedure for in situ detection of proteins and signaling pathways in
companion diagnostics. This will offer the medical industry pow-
erful, universally applicable tools for clinical research and routine
diagnostics.
CONCLUSION
Affinity proteomics for the analysis of proteins as companion diag-
nostics requires access to reagents that can be used in specific
detection reactions. The comprehensive validation and improve-
ment of existing and newly generated antibodies to obtain well
characterized, high-quality, and well-controlled resources as tools
for large scale studies of the human proteome in health and disease
is a widely acknowledged demand. In many routine clinical, diag-
nostic, and life science applications, antibodies have proven to be
the reagents of choice. IHC is routinely performed in the major-
ity of clinical laboratories and widely acknowledged as superior
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to other analysis techniques regarding time- and cost-effective
application. In selected cases, IHC and mutation-specific anti-
bodies may even provide an attractive alternative to DNA-based
testing methods. As a highly valuable resource documenting the
availability and identification of novel biomarker candidates, the
Human Protein Atlas2 project has generated antibodies targeting
proteins from over 15,000 genes, corresponding to about 75%
of all human protein-coding genes (133, 134). All antibodies are
routinely subjected to a series of validation steps, including pro-
tein arrays, western blots, and immunofluorescence and used to
assess protein expression patterns in a broad spectrum of nor-
mal and cancer tissues through application of IHC. Nevertheless,
efforts to detect proteins when high specificity is required often
fail. Hence, there is a strong need for better methods and reagents
for assessing protein expression in tissues as means of companion
diagnostics and alternative binders or PLA in combination with
existing antibodies represent promising candidate alternatives.
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